High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

Hagop Kantarjian, Moshe Talpaz, Susan O'Brien, Guillermo Garcia-Manero, Srdan Verstovsek, Francis Giles, Mary Beth Rios, Jianqin Shan, Laurie Letvak, Deborah Thomas, Stefan Faderl, Alessandra Ferrajoli, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94%. By quantitative polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major molecular response (QPRC < 0.05%; P = .00001), and complete molecular response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML.

Original languageEnglish (US)
Pages (from-to)2873-2878
Number of pages6
JournalBlood
Volume103
Issue number8
DOIs
StatePublished - Apr 15 2004
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Chromosomes
Cytogenetics
Therapeutics
Imatinib Mesylate
Polymerase chain reaction
Survival Rate
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. / Kantarjian, Hagop; Talpaz, Moshe; O'Brien, Susan; Garcia-Manero, Guillermo; Verstovsek, Srdan; Giles, Francis; Rios, Mary Beth; Shan, Jianqin; Letvak, Laurie; Thomas, Deborah; Faderl, Stefan; Ferrajoli, Alessandra; Cortes, Jorge.

In: Blood, Vol. 103, No. 8, 15.04.2004, p. 2873-2878.

Research output: Contribution to journalArticle

Kantarjian, H, Talpaz, M, O'Brien, S, Garcia-Manero, G, Verstovsek, S, Giles, F, Rios, MB, Shan, J, Letvak, L, Thomas, D, Faderl, S, Ferrajoli, A & Cortes, J 2004, 'High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia', Blood, vol. 103, no. 8, pp. 2873-2878. https://doi.org/10.1182/blood-2003-11-3800
Kantarjian, Hagop ; Talpaz, Moshe ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Verstovsek, Srdan ; Giles, Francis ; Rios, Mary Beth ; Shan, Jianqin ; Letvak, Laurie ; Thomas, Deborah ; Faderl, Stefan ; Ferrajoli, Alessandra ; Cortes, Jorge. / High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. In: Blood. 2004 ; Vol. 103, No. 8. pp. 2873-2878.
@article{e18253dfc3454e11a7fae4d4840a4773,
title = "High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia",
abstract = "Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96{\%}) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35{\%}), and 103 (90{\%}) had a complete response (Ph 0{\%}). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94{\%}. By quantitative polymerase chain reaction (QPCR) studies, 71 (63{\%}) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05{\%}, and 31 (28{\%}) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major molecular response (QPRC < 0.05{\%}; P = .00001), and complete molecular response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82{\%} of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML.",
author = "Hagop Kantarjian and Moshe Talpaz and Susan O'Brien and Guillermo Garcia-Manero and Srdan Verstovsek and Francis Giles and Rios, {Mary Beth} and Jianqin Shan and Laurie Letvak and Deborah Thomas and Stefan Faderl and Alessandra Ferrajoli and Jorge Cortes",
year = "2004",
month = "4",
day = "15",
doi = "10.1182/blood-2003-11-3800",
language = "English (US)",
volume = "103",
pages = "2873--2878",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

AU - Kantarjian, Hagop

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Verstovsek, Srdan

AU - Giles, Francis

AU - Rios, Mary Beth

AU - Shan, Jianqin

AU - Letvak, Laurie

AU - Thomas, Deborah

AU - Faderl, Stefan

AU - Ferrajoli, Alessandra

AU - Cortes, Jorge

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94%. By quantitative polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major molecular response (QPRC < 0.05%; P = .00001), and complete molecular response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML.

AB - Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94%. By quantitative polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major molecular response (QPRC < 0.05%; P = .00001), and complete molecular response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML.

UR - http://www.scopus.com/inward/record.url?scp=11144354274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354274&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-11-3800

DO - 10.1182/blood-2003-11-3800

M3 - Article

C2 - 15070658

AN - SCOPUS:11144354274

VL - 103

SP - 2873

EP - 2878

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -